Dr Clare Coveney is a Research Associate within the Biological Mass Spectrometry & Clinical Proteomics group in the John van Geest Cancer Research Centre .
The John van Geest Cancer Research Centre incorporates state-of-the-art technologies for discovering the genetic basis of the disease and developing new methods of diagnosis and treatment, and is therefore well equipped for the challenge of modern day cancer research.
Dr Coveney gained a BSc Pharmacolgy and Neuroscience (Hons) degree at Nottingham Trent University in 2007, within this she worked as a Research Assistant biobanking clinical samples from Derby City General Hospital and gained a diploma in professional skills. On completion she took a post as a Research Assistant running large cohorts of samples from a European collaboration using MALDI mass spectrometry. She continued working within the evolving proteomic mass spectrometry group as the facility became part of the newly established John van Geest Cancer Research Centre in 2010. There, she contributed to multiple clinical collaborations while completing a PhD P/T Evaluating Proteomic and Transcriptomic Biomarker Discovery Technologies in Ovarian Cancer.
Dr Coveney is keen to explore and develop techniques in biological mass spectrometry, acquiring proteomic data sets from an increasing range of sample biological substrates; serum, urine, saliva, cell lysate, secretome whilst exploring large multidimensional datasets and the ever-emerging pipelines to analyse and extract data from them.
Dr Coveney maintains the biological mass spectrometry facility in the John van Geest Cancer Research Centre, this currently houses 2 SCIEX TripleTOF instruments (5600+ and 6600) able to run either nano or microflow ESI. The current workflow utilises DIA/SWATH technology for label free quantitative proteomic profiling to identify differentially expressed proteins between sample groups, and generate semiquantitative data for as wider proteome coverage as possible.
The current set up is ideal for biomarker discovery experiments, aiming to identify protein biomarkers as predictors of disease status and response to therapy. Sitting within the JVGCRC research projects focused on prostate and breast cancer and diversified into collaborations in melanoma, Leukemea, Lymphangioleiomyomatosis (LAM), Chronic Obstructive Pulmonary Disease (COPD), Alzheimer's, Diabetes, kidney disease, skin healing among others.
Developing optimal workflows to generate and analyse multidimentional proteomic profiles from a wide range of samples is a fascinating way to contribute to knowledge in increasingly diverse fields.
Homocitrullination of lysine residuesmediated by myeloid derived suppressor cells in the tumour environment is an excellent target for cancer immunotherapy. Cool K., Xue W., Symonds P., Daniels I., Gijon M., Boocock DJ., Coveney C., Miles A., Shah S., Atabani A., Choudhury R., Vaghela P., Metheringham R., Brentville R., Durrant L. Journal for Immunotherapy of Cancer, in press.
Multiomic analysis of stretched osteocytes reveals processes and signalling linked to bone regeneration and cancer. Santos, L., Ugun-Klusek, A., Coveney, C. and Boocock, D.J., 2021. npj Regenerative Medicine, 6: 32. ISSN 2057-3995
β2-Adrenergic Signalling Promotes Cell Migration by Upregulating Expression of the Metastasis-Associated Molecule LYPD3. Michael Gruet, Daniel Cotton, Clare Coveney, David J. Boocock, Sarah Wagner, Lucie Komorowski, Robert C. Rees, A. Graham Pockley, A. Christopher Garner, John D. Wallis, Amanda K. Miles, and Desmond G. Powe. Biology. 9:2
Tipifarnib Modulates Interferon (IFN)-γ-Inducible Genes in Acute Myeloid Leukemia.. Vadakekolathu, Jayakumar & Reeder, Stephen & Coveney, Clare & Rutella, Sergio Blood 134. 2726-2726. 10.1182/blood-2019-124717.
The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis. Miller, S., Coveney, C., Johnson, J., FarmakiI, A., Gupta, N., Tobin, M.D., Wain, L.V., McCormack, F.X., Boocock, D.J. and Johnson, S.R., European Respiratory Journal, 52 (5): 1800951. ISSN 0903-1936
Proteomic profiling reveals the transglutaminase-2 externalization pathway in kidneys after unilateral ureteric obstruction. URINI, G., SCHROEDER, N., HUANG, L., BOOCOCK, D., SCARPELLINI, A., COVENEY, C., TONOLI, E., RAMASWAMY, R., BALL, G., VERDERIO, C., JOHNSON, T.S. and VERDERIO, E.A.M., Journal of the American Society of Nephrology. ISSN 1046-6673
Identification and characterisation of NANOG+/OCT-4high/SOX2+ doxorubicin-resistant stem-like cells from transformed trophoblastic cell lines Balahmar, R.M., Boocock, D.J., Coveney, C., Ray, S., Vadekolathy, J., Regad, T., Ali, S. and Sivasurbramaniam, S., Oncotarget. ISSN 1949-2553
A new inhibitor of glucose-6-phospate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo. Mele, L., Paino, F., Papaccio, F., Rregad, T., Boocock, D., Stiuso, P., Lombardi, A., Liccardo, D., Aquino, G., Barbieri, A., Arra, C., Coveney, C., LA Noce, M., Papaccio, G., Caraglia, M., Tirno, V. and Desidero, V., Cell Death & Disease, 9: 572.
A1 adenosine receptor-induced phosphorylation and modulation of transglutaminase 2 activity in H9c2 cells: A role in cell survival. Vyas FS, Hargreaves AJ, Bonner PLR, Boocock DJ, Coveney C, Dickenson JM.
The origins of the Selden Map of China - scientific analysis of the painting materials and techniques using a holistic approach. Kogou S, Neate S, Coveney C, Miles A, Boocock D, Burgio L, Cheung CS and Liang H. Heritage Science, pp.1–24.
Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer. Coveney C, Boocock D, Rees R, Deen S, Ball G. Microarrays, 4(3), pp.324–338.
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers. Abdel-Fatah TM, Arora A, Moseley P, Coveney C, Perry C, Johnson K, Kent C, Ball G, Chan S. BBA Clinical, 2, pp.10–17.
Exploration of ovarian cancer microarray data focusing on gene expression patterns relevant to survival using artificial neural networks. Coveney, C., Tong, D. L., Boocock, D. J., Rees, R. C., & Ball, G. R. (2014) IWBBIO
Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. Vafadar-Isfahani B, Ball G, Coveney C, Lemetre C, Boocock D, Minthon L, Hansson O, Miles AK, Janciauskiene SM, Warden D, Smith AD, Wilcock G, Kalsheker N, Rees R, Matharoo-Ball B, Morgan K.J Alzheimers Dis. 2012;28(3):625-36.
MS-Labeller: Bioinformatics support for quality assessment on high resolution mass spectrometry sample. Tong, D. L., Coveney, C., & Ball, G. R. (2012)., 25(Bhi), 964–967.
A simpler method of preprocessing MALDI-TOF MS data for differential biomarker analysis: stem cell and melanoma cancer studies. Tong DL, Boocock DJ, Coveney C, Saif J, Gomez SG, Querol S, Rees R, Ball GR. Clin Proteomics. 2011 Sep 19;8:14. doi: 10.1186/1559-0275-8-14.
Serum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model. Vafadar-Isfahani B, Laversin SA, Ahmad M, Ball G, Coveney C, Lemetre C, Kathleen Miles A, van Schalkwyk G, Rees R, Matharoo-Ball B.Proteomics Clin Appl. 2010 Sep;4(8-9):682-96. doi: 10.1002/prca.200900218.